Skip to main content
If you continue browsing this website, you agree to our policies:
  • Terms and Conditions
  • Privacy & Cookies Policy
Continue
x
 Logo of the company, returns to the landing page after login.
  • Home
  • Glossary
  • EUPATI website
  • Learning Library
  • Pathways
  • More
English ‎(en_wp)‎
Català ‎(ca_wp)‎ English ‎(en_wp)‎ Français ‎(fr_wp)‎ Português - Portugal ‎(pt)‎ Ελληνικά ‎(el_wp)‎
Log in

    Side Drawer

    EUPATI Open Classroom
    Profile Home Glossary EUPATI website Learning Library Pathways

    Glossary

    Back

    New Drug Application

    A New Drug Application (NDA) is a document submitted to the Food and Drug Administration (FDA) to request authorisation to market a medical product in the United States. The information in the NDA must allow the FDA to make the following judgements (quoted from FDA website):

    - 'Whether the drug is safe and effective in its proposed use(s), and whether the benefits of the drug outweigh the risks
    - Whether the drug's proposed labelling (package insert) is appropriate, and what it should contain.
    - Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity.'

    The NDA must include information about the medicine's ingredients, outcomes of the animal and clinical studies, how it behaves in the body, and how it is manufactured and packaged.

    » Glossary

    Previous Activity
    Next Activity

    Footer

    You are not logged in. (Log in)
    Policies
    Get the mobile app
    Powered by Moodle
     

    The EUPATI Open Classroom is supported by the EUPATI Reload project, funded by EIT Health. EIT Health is supported by EIT, a body of the European Union. 

    For more information about EUPATI, please access our website www.eupati.eu or contact us at info@eupati.eu.

    EIT Health logo and EU logo

    Terms and Conditions

    Privacy and Cookie Policy

    © 2024 EUPATI

    Select banner image